Related Experiment Videos
A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells
1Division of Oncology, Department of Medicine, Albert Einstein College of Medicine and the Albert Einstein Cancer Center, Bronx, New York 10461, USA.
Abstract:
Recent studies have indicated that the development of cyclin-dependent kinase (cdk)2 inhibitors that deregulate E2F are a plausible pharmacological strategy for novel antineoplastic agents. We show here that 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516), a novel 3-substituted indolinone compound, binds to and selectively inhibits the activity of cdk2. This inhibition results in a time-dependent decrease (4-64%) in the phosphorylation of the retinoblastoma protein pRb, an increase in caspase-3 activation (5-84%), and alterations in cell cycle resulting in either a G(0)-G(1) or a G(2)-M block. We also report here cell line differences in the cdk-dependent phosphorylation of pRb. These findings demonstrate that SU9516 is a selective cdk2 inhibitor and support the theory that compounds that inhibit cdk2 are viable resources in the development of new antineoplastic agents.
Insights
The novel compound SU9516 selectively inhibits cyclin-dependent kinase 2 (cdk2), a key target for cancer drugs. This inhibition disrupts cell cycle progression, offering a promising strategy for developing new antineoplastic agents.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Background:
- Cyclin-dependent kinase (cdk)2 inhibitors targeting E2F deregulation are a potential strategy for novel antineoplastic agents.
- Selective inhibition of cdk2 is crucial for developing effective cancer therapies.
Purpose of the Study:
- To investigate the inhibitory effects of SU9516 on cdk2 activity.
- To evaluate the downstream effects of SU9516-induced cdk2 inhibition on retinoblastoma protein (pRb) phosphorylation, caspase-3 activation, and cell cycle progression.
- To explore potential cell line variations in cdk-dependent pRb phosphorylation.
Main Methods:
- Biochemical assays to determine SU9516 binding and selective inhibition of cdk2.
- Western blotting to assess pRb phosphorylation levels.
- Caspase-3 activity assays.
- Flow cytometry to analyze cell cycle distribution.
Main Results:
- SU9516 selectively binds to and inhibits cdk2 activity.
- Inhibition of cdk2 by SU9516 leads to decreased pRb phosphorylation (4-64%) and increased caspase-3 activation (5-84%).
- SU9516 induces cell cycle arrest at either the G(0)-G(1) or G(2)-M phase, with observed cell line-specific differences in pRb phosphorylation.
Conclusions:
- SU9516 is a potent and selective cdk2 inhibitor.
- These findings support the therapeutic potential of cdk2 inhibitors in cancer treatment.
- SU9516 represents a viable resource for the development of new antineoplastic agents.